New Jersey Law Journal: Evidentiary Clash Prompts Reversal of US$83M in Pelvic Mesh Verdicts Against J&J, Bard
March 2, 2021
Johnson & Johnson and C.R. Bard are no longer liable for $83 million in damages after a New Jersey appeals court found that evidence of the companies’ FDA clearance for their vaginal mesh products was wrongfully excluded during trial, this article noted.
According to the publication, the court’s ruling indicated that excluding evidence of the Section 510(K) clearance deprived Johnson & Johnson and C.R. Bard of a fair trial, including in relation to the award of punitive damages.
O’Melveny partner Steve Brody and counsel Jason Zarrow advised Johnson & Johnson on the matter.
New Jersey Law Journal subscribers can read the full article here.